Gates Package — page 157

Bill & Melinda Gates Foundation- National Institutes of Health 8:30 A.M. -- 8:35 A.M. 8:35 A.M. -- 8:45 A.M. 8:45 A.M. -- 9:30 A.M. 9:30 A.M. -- 10:15 A.M. 10:15 A.M. - 10:45 A.M. 10:45 A.M. -- 11:30 P.M. Fourth Annual Consultative Workshop June 2, 2017 John Edward Porter Neuroscience Research Center 35 Convent Drive Bethesda, MD DRAFT Welcome Francis S. Collins, MD, PhD, Director, National Institutes of Health (NIH) Trevor Mundel, MD, PhD, President, Global Health Division, Bill & Melinda Gates Foundation (BMGF) Opening Remarks Bill Gates, Co-Chair and Trustee, Bill & Melinda Gates Foundation Panel 1: Vaccine R&D developments: Challenges and opportunities in therapeutic and preventive vaccine R&D for HPV and other cancer causing viruses Douglas R. Lowy, MD, Acting Director, National Cancer Institute (NCI), NIH Jeffrey Cohen, MD, Chief, Laboratory of Infectious Diseases, NIAID, NIH Peter Dull. MD, Deputy Director, Integrated Clinical Vaccine Development, Bill & Melinda Gates Foundation Kirsten Vogelsong, PhD, Senior Program Officer, Contraceptive Development, Family Planning; Bill & Melinda Gates Foundation Panel 2: Vaccine R&D developments: Structure-based immunogen design Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID), NIH John Mascola, MD, Director, Vaccine Research Center and Chief, Virology Laboratory, NIAID, NIH Lynda Stuart, MD, PhD, Deputy Director, Vaccines and Host-Pathogen Biology, Discovery and Translational Sciences Division, Bill & Melinda Gates Foundation Amy Weiner, PhD, Senior Program Officer, Discovery and Translational Sciences Division, Bill & Melinda Gates Foundation Coffee Break Panel 3: Point-of-care diagnostics for low-resource settings Daniel J. Wattendorf, MD, Director, Innovative Technology Solutions, Bill